The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
Yahoo Finance

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif., February 04, 2025--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline ...
The American Journal of Managed Care

FDA Approves FoundationOne CDx as Companion Diagnostic for Niraparib/Abiraterone in mCRPC

The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker ...

Foundation Medicine is one of the chief contributors to ComboMATCH, an initiative to test biomarker-targeted cancer treatment combinations ...
Nasdaq

Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for LYNPARZA® to Identify Patients with HRR-Mutated Metastatic Castration ...

LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...
Business Wire

Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services ...
Business Wire

Foundation Medicine Launches FoundationOne™

FoundationOne interrogates all genes somatically altered in human solid tumors that are validated targets for therapy or drivers of oncogenesis based on current knowledge. It reveals all classes of ...
Healio

FDA approves FoundationOne CDx to identify patients with MSI-high tumors for pembrolizumab

Please provide your email address to receive an email when new articles are posted on . The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite ...
PharmiWeb

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

CAMBRIDGE, Mass. & AUSTIN, Texas--(BUSINESS WIRE)--Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, ...
Pharmabiz

Chugai obtains approval for FoundationOne CDx Cancer Genomic Profile to be used as a companion diagnostic for PARP inhibitor, Talazoparib

Chugai Pharmaceutical Co., Ltd. announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) on February 2, 2024, for FoundationOne CDx Cancer Genomic Profile to be ...
BioWorld

Items Tagged with 'Foundationone CDx'

Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of ...